EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition

Trial ID # NCT03579316
Phase II
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Olaparib
Alternate Drug Names AZD2281, Lynparza
Drugs in Trial Adavosertib, Olaparib
Eligible Participant

Recurrent ovarian cancer with progression on or after prior PARP inhibitor

Patients Enrolled

80 patients, median 4 prior therapies (1-11), 64% Pt-R, 48% BRCA MUT

Therapy Setting



ORR, DCR, DoR, PFS, evaluated per RECIST


Exploratory: BRCA status


A randomized two-arm non-comparative phase II
Ada (n=35): ORR: 23% (8PR); DoR: 5.5 months: DCR (4 months): 63% (8PR, 14SD); PFS: 5.5 months
Ada+Ola (n=35): ORR: 29% (10PR); DoR: 6.4 months: DCR (4 months): 89% (10PR, 21SD); PFS: 6.8 months

Exploratory analysis, BRCA status:
Ada+Ola (n=16) vs Ada (n=15): ORR: 19 vs 20%; DoR: 6.4 vs 5.6 months; DCR (4 months): 81 vs 67%; PFS: 5.6 vs 5.6 months
Ada+Ola (n=18) vs Ada (n=16): ORR: 39 vs 31%; DoR: 8.7 vs 4.1 months; DCR (4 months): 94 vs 69%; PFS: 8.4 vs 4.1 months

Clinically Significant Adverse Events

Ada+Ola vs Ada:
Serious AE: none
Grade 3-4 AE: thrombocytopenia (20 vs 11%), neutropenia (14 vs 13%), diarrhea (12 vs 8%), fatigue (12 vs 3%), anemia (10 vs 3%)


Adavosertib alone and in combination with olaparib demonstrates efficacy in patients with PARPi-resistant ovarian cancer irrespective of BRCA status. Toxicities observed on both arms are generally manageable with supportive care, dose interruptions and dose reductions as needed.


Westin SN et al. EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. J Clin Oncol (2021) 39 (suppl 15; abstr 5505)

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.